Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chemokine receptors CCR6 and CCR7 have been reported to play important roles in T cell migration and organ-specific metastasis of various tumors.
|
23835793 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that EVI1 is a critical player in tumor growth in a subset of MLL-rearranged AMLs.
|
22553314 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The pooled relative risks indicated CCR7 expression was significantly associated with deeper tumor invasion [0.61, 95 % confidence interval (CI) 0.45-0.84, p = 0.003], advanced stage (0.47, 95 % CI 0.32-0.69, p < 0.001), vascular invasion (2.12, 95 % CI 1.20-3.73, p = 0.009), lymph node metastasis (2.00, 95 % CI 1.48-2.70, p < 0.001), and lymphatic invasion (1.98, 95 % CI 1.43-2.72, p < 0.001) but not with age, tumor size, and histological type.
|
26984468 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among these genes, increased expression of CCR7 in CD44+ CSCs was confirmed in NPC xenografts and primary tumors.
|
23285037 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Evidence supports a role for EVI1 in inducing cellular quiescence, and this may contribute to the resistance to chemotherapy seen in patients with neoplasms that overexpress EVI1.
|
24495476 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Knockdown of TAB1 attenuated CCR7 expression and tumor growth in an orthotopic animal study.
|
25557171 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings open the way to further studies aimed at identifying the culprit EVI1 implicated tumour suppressor genes on 7q.
|
20084277 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Negative Dicer 1 protein and let-7a miRNA expression and positive CCR7 protein expression significantly correlated with lymph node metastasis, depth of invasion, high clinical TNM stage, and larger tumor size.
|
23519840 |
2013 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The blast crisis of CML has been variably associated with abnormalities of proto-oncogenes, such as RAS and MYC, or of tumour suppressor genes, in particular RB, p53 and p16, or with the generation of chimeric transcription factors, as in the AML1-EVI1 gene fusion.
|
8656667 |
1996 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ccr7 gene expression is controlled by the activity of the T-ALL oncogene Notch1 and is expressed in human tumours carrying Notch1-activating mutations.
|
19536265 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High-intensity IHC staining for CXCR4 was associated with larger tumor size (P = .02), while PTCs exhibiting ETE, ALI, or lymph node metastasis showed higher-intensity IHC staining for CCR7 than those without (P = .01, .03, and .01, respectively).
|
18696160 |
2008 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We showed that increased CCR7 expression was significantly associated with positive lymph node status (P=0.008), pT3-T4 tumor stage (P=0.015), tumor grade (P=0.010) and worse overall survival (OS, P<0.001) and that both CCR7 expression and lymph node metastasis were independent prognostic factors for OS (P=0.031 and P=0.001, respectively) based on multivariate analysis.
|
28534984 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of chemokine receptors CCR7 has been studied in relation to tumor dissemination and poor prognosis in a limited number of cancers.
|
21548969 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Strong cytoplasmic staining for CCR7 correlated with the presence of epithelioid cells (P = 0.037), tumor thickness (P = 0.011), lymphocytic infiltration (P = 0.041), and necrosis (P = 0.045).
|
24052640 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Matured DCs (≥ 60% upregulation of CD80, CD86, CD83, and CCR7) produced high levels of the Th1 effector cytokine, IL12-p70 (1.2 ng/ml; p < 0.0001), compared to DCs pulsed with tumour lysate, or matured with an interferon-containing cocktail alone.
|
30283982 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The chemokine receptor CCR7 and its ligands CCL19/21 mediate the tumor mobility, invasion, and metastasis (Wu et al.Curr Pharm Des.15:742-57, 2009).
|
25168373 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Experimental re-expression of MS4A3 in an EVI1 overexpressing cell line counteracted the tumor promoting effect of EVI1 in a murine xenograft model by increasing the rate of apoptosis.
|
25886616 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Freshly sorted metastatic cells and tumour cell lines derived from the liver of BALB/c mice overexpressed functional CCR6 and CCR7 molecules compared with primary tumour.
|
12791091 |
2003 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CCR7(+) tumor cells and FOXP3(+) Tregs were assessed by immunohistochemistry in tissue microarrays containing gastric cancer from 133 patients.
|
24040244 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In diverse tumor entities, expression of the chemokine receptor, CCR7, has been linked to tumor dissemination and poor prognosis.
|
16786131 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that specific HDAc inhibitors may be useful in the treatment of Evi-1-induced neoplastic tumors, including myeloid leukemias.
|
11587364 |
2001 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CC-chemokine receptor 7 (CCR7), another protein involved in angiogenesis, is strongly expressed in most human cancers, where it activated promotes tumor growth as well as favoring tumor cell invasion and migration.
|
26722441 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The RUNX1/EVI1 chimeric transcription factor produced by t(3;21) causes leukemic transformation in hematopoietic stem cell tumors, possibly through a differentiation block of malignant myeloid progenitors.
|
17894555 |
2007 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the prognosis of patients with CCR7-positive tumors was better than that of patients with CCR7-negative tumors, but no such correlation was observed for CXCR4 expression.
|
15867478 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As tyrosine kinase inhibitors for metastatic renal cell carcinoma (mRCC) mostly emphasized on vascular inhibition, whether the CCR7 expressing tumor cells with potential lymphatic invasion function could have an impact on mRCC patient's drug response and survival, was unknown.
|
28114889 |
2017 |